Li Gan, PhD, wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.
When researchers like Gan find potential new drugs, it’s useful to test them on human cells to increase the chances that they will benefit patients. Historically, these tests have been conducted in cancer cells, which often don’t match the biology of human brain cells.
“The problem is that brain cells from actual people don’t survive well in a dish, so we need to engineer human cells in the lab,” explained Gan, senior investigator at the Gladstone Institutes. “But, that’s not as simple as it may sound.”
Many scientists use induced pluripotent stem cells (iPSCs) to address this issue. IPSCs are made by reprogramming skin cells or blood cells to become stem cells, which can then be transformed into any type of cell in the body. Gan uses iPSCs to produce brain cells, such as neurons or glial cells, because they are relevant to neurodegenerative disease.
Human brain cells derived from iPSCs offer great potential for drug screening. Yet, the process for producing them can be complicated, expensive, and highly variable. Many of the current methods produce cells that are heterogeneous, or different from one another, and this can lead to inconsistent results in drug screening. In addition, producing a large number of cells is very costly, so it’s difficult to scale up for big experiments.
A new platform developed in Gan’s lab will now allow scientists to overcome these constraints
A New Technique Is Born
“I came across a new method to produce iPSCs that was developed at Stanford,” said Michael Ward, MD, PhD, a former staff scientist in Gan’s lab who is now an investigator at the National Institutes of Health. “I thought that if our team could find a way to simplify and better control that approach, we might be able to improve the way we engineer human brain cells in the lab.”
Ward and his colleague Chao Wang, PhD, discovered a way to manipulate the genetic makeup of cells to produce thousands of neurons from a single iPSC. This meant that every engineered brain cell was now identical.
“I was truly motivated by our initial results,” said Gan, who is also a professor of neurology at UC San Francisco. “I had observed too much variability using the traditional methods, which made reproducing experiments quite problematic. So, the ability to produce homogeneous human brain cells was very exciting.”
The team further improved the technique to create a simplified, two-step process. This allows scientists to precisely control how many brain cells they produce and makes it easier to replicate their results from one experiment to the next.
Their technique also greatly accelerates the process. While it would normally take several months to produce brain cells, Gan and her team can now engineer large quantities of them within 1 or 2 weeks, and have functionally active neurons within 1 month.
The researchers realized this new approach had tremendous potential to screen drugs and to study disease mechanisms. To prove it, they tested it in their own research.
They applied their technique to produce human neurons by using iPSCs. Then, they developed a drug discovery platform and screened 1,280 compounds. Their goal is to identify the compounds that could lower levels of the protein tau in the brain, which is considered one of the most promising approaches in Alzheimer’s research and could potentially lead to new drugs to treat the disease.
“We showed that we can engineer large quantities of human brain cells that are all the same, while also significantly reducing the costs,” said Wang, Gladstone postdoctoral scholar. “This means our technology can easily be scaled up and can essentially be used to screen millions of compounds.”
A Powerful Tool for the Entire Scientific Community
“We have developed a cost-effective technology to produce large quantities of human brain cells in two simple steps,” summarized Gan. “By surmounting major challenges in human neuron-based drug discovery, we believe this technique will be adopted widely in both basic science and industry.”
Word of this useful new technology has already spread, and people from different scientific sectors have come knocking on Gan’s door to learn about it. Her team has shared the new method with scores of academic colleagues, some of whom had no experience with cell culture. So far, they all successfully repeated the two-step process to produce their own cells and facilitate scientific discoveries.
Details of this new technique were published on October 10, 2017, in the scientific journal Stem Cell Reports.
With some of the roadblocks out of the way, Gan hopes more discoveries will soon help the millions who suffer from Alzheimer’s disease and related conditions.
Learn more: Growing Human Brain Cells in the Lab
The Latest on: Drug discovery
- Drug Discovery Services Market - Recommendations to Market Players to Stay Ahead of the Competition on November 22, 2017 at 12:52 pm
The global drug discovery services market can be segmented into Europe, North America, Latin America, Asia Pacific, and the Rest of the World. Of these, it is anticipated that North America will continue to lead in the market on account of the early ... […]
- Cloud-based Drug Discovery Platforms Market: Pharmaceutical Vendors Projected to be the Most Attractive End User Segment Through 2025 on November 22, 2017 at 6:07 am
New York City, NY, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Small and medium pharmaceutical companies to present significant opportunities for investment in the global cloud-based drug discovery platform market Among the various end users of cloud-based drug ... […]
- Lab-Made Organoids for Drug Discovery on November 21, 2017 at 2:55 pm
When you think of cellular model systems to study disease and potential therapeutics in a human context in the lab, you traditionally would think of animal models or 2-dimensional cell culture systems where primary or immortalized cells grow on plastic ... […]
- Lab-Grown Mini Organs Could Speed Up Drug Discovery on November 20, 2017 at 8:34 am
The thought of lab-grown organs conjures up Frankenstein-like imagery. The reality however, is somewhat less visually dramatic, with the term ‘organoids’ used to describe tiny 3D structures of human tissue, a millimeter or so in diameter. Although ... […]
- 2017 Technologies Empowering Drug Discovery and Development - Research and Markets on November 20, 2017 at 6:39 am
DUBLIN--(BUSINESS WIRE)--The "Technologies Empowering Drug Discovery and Development" report has been added to Research and Markets' offering. This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across new approaches fueling ... […]
- Abbvie and Astrazeneca to present keynote address’ at SMi’s Drug Discovery 2018 on November 16, 2017 at 12:00 am
SMi reports: Abbvie and Astrazeneca to present keynote address’ at SMi’s Drug Discovery conference taking place in London on 21 st-22 nd March 2018 Abbvie and Astrazeneca will present keynote address’ at SMi’s Drug Discovery conference taking place ... […]
- Two Leading Drug Hunters Join Charles River on November 15, 2017 at 12:00 am
The drug discovery industry is at a point of unprecedented innovation. With enabling technologies like CRISPR, AI, and recent Nobel-award-winning technology cryo-electron microscopy (cryo-EM) opening new doors, there is a feeling that we have an ... […]
- Cloud-based Drug Discovery Platform Market to Reach US$ 4,323.5 Million by 2025 - Persistence Market Research on November 9, 2017 at 5:17 am
A new report by Persistence Market Research presents interesting facets of the global cloud-based drug discovery platform market and provides value forecasts for an eight year period from 2017 to 2025. The report titled 'Cloud-based Drug Discovery Platform ... […]
via Google News and Bing News